Pfizer Inc. has a 6% yield and 8.49x P/E with new cancer drugs and GLP-1 therapies to offset 2026-2028 LOE cycles. Read why ...

CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare ...

Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted a 2028 launch. CEO Albert Bourla explained the pharma's strategy at J.P.

First patients dosed in DAYBreak™ registrational program for bexobrutideg in relapsed/refractory CLLPresented Phase 1 results at ASH 2025 that ...

Aclaris Therapeutics reported early study results showing its ATI-2138 drug drove rapid and lasting hair regrowth, ...

Baseline Therapeutics, Inc. (baseline-tx.com) is a San Francisco-based clinical-stage biotechnology company developing breakthrough therapeutics for addiction. Baseline's lead program, BT-001, is a ...

AgomAb Therapeutics NV ( AGMB) has filed to raise $200 million in development capital in an IPO of its American Depositary Shares representing underlying common shares, according to SEC F-1/A ...

Roche, a Swiss pharmaceutical company, reported on the 27th, local time, that its obesity treatment pipeline ‘CT-388’ ...

Pfizer is gearing up for a consumer-driven obesity drug market, drawing parallels to the demand surge it experienced with the launch of Viagra (sildenafil), CEO Albert Bourla said at the 44th Annual ...

While Baseline Therapeutics declined to disclose its starting capital, the startup said it will use the funds to push its GLP ...

After a years-long revenue drought, there's a light at the end of the tunnel.